**APPENDIX**

**Appendix Table 1: Factors associated with death among HIV-infected cervical cancer patients (Nadir CD4, n=228 excluding patients with final stage IA)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** |  | **Crude HR (95% CI)** | **Adjusted HR (95% CI)** |
| Nadir CD4 cells/mm3 (continuous by 100) |  | 0.93 (0.84-1.04) | 0.95 (0.84-1.07) |
| Age (years) |  | 1.00 (0.97-1.03) | 1.01 (0.98-1.03) |
| Number of chemo cycles | None | 1.00 | 1.00 |
|  | 1-5 | **0.37 (0.23-0.61)** | 0.61 (0.34-1.12) |
|  | Missing | 0.97 (0.42-2.24) | 1.07 (0.43-2.71) |
| Hemoglobin (g/dl) at baseline | 1st quartile(3.7-9.0) | 1.00 | 1.00 |
|  | 2nd quartile(9.1-10.4) | 1.18 (0.64-2.18) | 1.18 (0.61-2.30) |
|  | 3rd quartile(10.5-12.1) | 0.60 (0.30-1.21) | 0.61 (0.29-1.29) |
|  | 4th quartile(12.2-15.3) | **0.36 (0.17-0.76)** | **0.43 (0.19-0.96)** |
|  | Missing | 1.67 (0.78-3.58) | 1.28 (0.57-2.86) |
| Stage | Stage IB | 1.00 | 1.00 |
|  | Stage II | 2.21 (0.67-7.24) | 1.46 (0.44-4.87) |
|  | Stage III | 3.13 (0.96-10.28) | 1.27 (0.36-4.55) |
|  | Stage IV | **3.88 (1.05-14.37)** | 0.84 (0.19-3.67) |
|  | Missing | 1.20 (0.20-7.20) | 0.61 (0.09-4.00) |
| RT dose (total EQD2) | 1st quartile(9.3-67.1) | 1.00 | 1.00 |
|  | 2nd quartile(67.2-77.9) | **0.41 (0.23-0.74)** | 0.52 (0.25-1.06) |
|  | 3rd quartile(78.0-79.8) | **0.31 (0.16-0.59)** | **0.30 (0.14-0.64)** |
|  | 4th quartile(79.9-90.0) | **0.31 (0.16-0.59)** | **0.33 (0.16-0.69)** |
| Performance status (KPS\*) | ≤ 80 | 1.00 | 1.00 |
|  | > 80 | 0.63 (0.37-1.06) | 0.61 (0.35-1.06) |
|  | Missing | 0.58 (0.27-1.22) | 0.46 (0.20-1.05) |

\*KPS: Karnofsky Performance Status

**Appendix Table 2: Factors associated with death among HIV-infected cervical cancer patients (Delta CD4, n=137 excluding patients with final stage IA )**

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** |  | **Crude HR (95% CI)** | **Adjusted HR (95% CI)** |
| Delta CD4 (cells/mm3)(Categorical) | < 100 | 1.00 | 1.00 |
|  | 100-249 | 0.59 (0.31-1.15) | **0.46 (0.22-0.97)** |
|  | ≥ 250 | **0.39 (0.19-0.80)** | **0.43 (0.19-0.96)** |
| Age (years) |  | 1.00 (0.96-1.03) | 1.02 (0.98-1.06) |
| Hemoglobin at baseline (g/dl) | 1st quartile(4.1-9.0) | 1.00 | 1.00 |
|  | 2nd quartile(9.1-10.4) | 1.42 (0.66-3.09) | 1.61 (0.66-3.96) |
|  | 3rd quartile(10.5-12.1) | 0.71 (0.28-1.81) | 0.72 (0.26-2.05) |
|  | 4th quartile(12.2-15.3) | 0.42 (0.16-1.11) | 0.45 (0.15-1.33) |
|  | Missing | 1.34 (0.46-3.93) | 1.37 (0.43-4.33) |
| Stage | Stage IB | 1.00 | 1.00 |
|  | Stage II | 3.65 (0.49-27.21) | 2.10 (0.27-16.52) |
|  | Stage III | 5.05 (0.68-37.60) | 1.92 (0.24-15.47) |
|  | Stage IV | 5.10 (0.61-42.41) | 1.30 (0.13-12.92) |
| RT dose (EQD2) | 1st quartile(9.3-63.9) | 1.00 | 1.00 |
|  | 2nd quartile(64.0-77.9) | **0.45 (0.21-0.95)** | 0.59 (0.24-1.48) |
|  | 3rd quartile(78.0-80.5) | **0.35 (0.16-0.75)** | 0.30 (0.12-0.76) |
|  | 4th quartile(80.6-89.5) | **0.35 (0.15-0.79)** | 0.41 (0.16-1.09) |
| Number of chemo cycles | None | 1.00 | 1.00 |
|  | 1-5 | **0.31 (0.17-0.57)** | **0.47 (0.23-0.97)** |
|  | Missing | 0.74 (0.28-1.99) | 1.15 (0.37-3.58) |
| Performance status (KPS\*) | ≤ 80 | 1.00 | 1.00 |
|  | > 80 | 0.81 (0.43-1.52) | 0.70 (0.34-1.43) |
|  | Missing | 0.34 (0.10-1.17) | **0.17 (0.04-0.68)** |
| Nadir CD4 cells/mm3 (continuous by 100) |  | 1.07 (0.92-1.25) | 1.04 (0.85-1.26) |

\*KPS: Karnofsky Performance Status